Results 201 to 210 of about 904,908 (258)

Pyroptosis in Preeclampsia: Placenta‐to‐Maternal Organ Communication, Molecular Mechanisms, and Therapeutic Targets

open access: yesComprehensive Physiology, Volume 16, Issue 6, December 2026.
Schematic diagram illustrating the potential mechanisms and core molecules contributing to the development of PE via mediating pyroptosis: focus on trophoblasts and endothelial cells. Pyroptosis of trophoblast cells in the placenta of preeclampsia not only inhibits its invasion, migration, and differentiation, causing local infiltration and ...
Xianyi Zhou   +5 more
wiley   +1 more source

2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part III) on Rate and Rhythm Control in Atrial Fibrillation. [PDF]

open access: yesJ Arrhythm
Chen M   +19 more
europepmc   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10961-10976, December 2026.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest   +3 more
wiley   +1 more source

Intravascular Ultrasound (IVUS)-Assisted Fenestrated Endovascular Aortic Repair (FEVAR) for Iuxtarenal Aortic Aneurysm with Pelvic Ectopic Left Kidney and Aberrant Left Renal Arteries: A Case Report. [PDF]

open access: yesReports (MDPI)
Nardi P   +14 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10931-10949, December 2026.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou   +5 more
wiley   +1 more source

Nephroprotective Effects of the Dual GCGR/GLP‐1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11915-11926, December 2026.
ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment of people living with obesity and metabolic dysfunction‐associated steatohepatitis.
Alexander Hamilton   +11 more
wiley   +1 more source

Catheter-Based Renal Denervation in Uncontrolled and Resistant Hypertension: Evidence, Guidelines, Special Populations and Clinical Implementation. [PDF]

open access: yesJ Cardiovasc Dev Dis
Skalidis I   +19 more
europepmc   +1 more source

Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine

open access: yesHistopathology, Volume 89, Issue 6, Page 1011-1019, December 2026.
CYP11B2 immunohistochemistry identifies aldosterone‐producing nodules and enables objective subtyping using the B2 ratio (B2R), defined as the size ratio between the largest and second‐largest CYP11B2‐positive nodules. A B2R ≥8.1 indicates classical histology with a dominant lesion and high likelihood of cure, whereas B2R <8.1 reflects non‐classical ...
Adam Stenman   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy